Allergan plc, has received approval from the U.S. Food and Drug Administration (FDA) to market ACZONE® (dapsone) Gel, 7.5%, a new prescription  opical treatment for acne in patients 12 years of age and older. ACZONE® Gel, 7.5%

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field